GKOS
GLAUKOS Corp
NYSE · Healthcare · Medical - Devices · US
$219.98
−10.83%Price chart
Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5
Key dataNov 5, 2026
Open$248.55
From 52W high−10.83%
Volume1.94M
Market cap$13.02B
P/E (TTM)—
P/S (TTM)18.9x
Div yield—
Key dataNov 5, 2026
Open
$248.55
From 52W high
−10.83%
Volume
1.94M
Market cap
$13.02B
ValuationView details →
P/E (Fwd)
152.4x
EV/EBITDA
−103.1x
P/E (TTM)
—
RSI (14)
70.2
MomentumView details →
1D Return
−10.83%
YTD Return
+106.70%
SummaryUpdated Sep 1, 2026
Glaukos Corporation (NASDAQ:GKOS) is a specialized ophthalmic medical technology and pharmaceutical company founded in 1998 and headquartered in San Clemente, California. The company went public in June 2015 and has established itself as a pioneer in minimally invasive glaucoma surgery (MIGS) and innovative ocular therapeutics. Glaukos focuses on developing and commercializing novel therapies for treating glaucoma, corneal disorders, and retinal diseases, with a particular emphasis on what it calls "interventional glaucoma" - a proactive approach to treating eye pressure and preventing vision loss before significant damage occurs.
Similar companies
Latest newsMore news →
GLAUKOS Corp shares rose 18% in premarket trading after the company reported an unexpected third-quarter profit.8d agoGLAUKOS Corp reported quarterly earnings of $0.47 per share, compared with a loss of $0.16 per share a year earlier, surpassing the Zacks consensus estimate of a loss of $0.12 per share.9d agoGlaukos Corp. reported third-quarter 2026 revenue of $211.0 million, net income of $2.0 million and diluted earnings per share of $0.03.9d ago